DEA Announces Public Hearing on Cannabis Rescheduling: What Dispensaries Need to Know

Introduction: On August 26, 2024, the Drug Enforcement Administration (DEA) announced a public hearing scheduled for December 2, 2024, to discuss the potential rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act. This decision could have significant implications for our dispensary partners and the broader cannabis industry.

Background: The process of rescheduling cannabis has been ongoing since August 2023, when the Department of Health and Human Services (HHS) recommended moving cannabis to Schedule III. The DEA followed up with a proposed rule in May 2024, leading to a public comment period that generated 43,000 responses, highlighting the widespread interest and high stakes involved.

The Hearing: The December 2 hearing in Arlington, Virginia, will be a crucial event in determining the future of cannabis regulation. It will bring together former DEA leaders and various stakeholders to discuss one of the most significant rulemakings in the agency's history. As co-chair of the Coalition for Cannabis Scheduling Reform, Dutchie, alongside our partners, has petitioned to participate in the hearing and expects to have a seat at the table.

What Happens Next: After the hearing, an Administrative Law Judge will review the proceedings and make a recommendation to the DEA Administrator. The final decision on whether to reschedule cannabis will then be made by the DEA Administrator. This multi-step process ensures that all perspectives are considered, but it also means that the outcome may take some time to be finalized.

Implications for Dispensaries: Rescheduling cannabis to Schedule III would mark a significant shift in federal policy, potentially easing some regulatory and financial burdens for dispensaries. However, with the hearing taking place after the upcoming presidential election, there is some uncertainty, which has already caused fluctuations in cannabis stock prices. There is now a significant risk that there is no final rule until 2025, meaning that 280E implications may not have impact for the 2024 Fiscal Year.

Dutchie’s Role and What’s Next: As a leading voice in the Coalition for Cannabis Scheduling Reform, Dutchie remains hopeful that the proposed rule will be finalized this year. We will continue to monitor developments closely and keep our customers informed. We encourage our dispensary partners to stay engaged and prepared for potential changes.

The DEA’s upcoming hearing is a pivotal moment for the cannabis industry. Dutchie is committed to supporting our dispensary partners through this period of change, advocating for outcomes that benefit the entire industry. Stay tuned for further updates as we navigate these developments together.

‍